Core Viewpoint - Health Road (02587) anticipates significant revenue and profit growth for the fiscal year 2025, projecting revenue of at least RMB 1.5 billion, a growth of no less than 25% compared to the fiscal year ending December 31, 2024, and a profit of no less than RMB 50 million, recovering from a net loss of RMB 269 million in 2024 [1][2] Group 1 - The expected positive performance is primarily attributed to an increase in content service revenue, projected to grow from RMB 577 million in 2024 to at least RMB 800 million in 2025, driven by strategic adjustments such as resource integration and new service models [2] - Information technology service revenue is expected to rise from RMB 296 million in 2024 to at least RMB 350 million in 2025, benefiting from growth in big data technology services and the launch of AI software products, which contributed approximately RMB 30 million in revenue in its first year [2] - Operational efficiency continues to improve, with total operating expenses (including administrative, sales, and R&D expenses) accounting for about 29% of revenue in 2024, expected to decrease as the business expands in 2025 [2]

Core Viewpoint - Health Road (02587) has announced a positive earnings forecast, expecting a revenue increase of at least 25% for the fiscal year 2025, leading to a significant stock price increase of over 14% following the announcement [1] Group 1: Financial Performance - The company anticipates revenue for the fiscal year 2025 to be no less than RMB 1.5 billion, compared to a projected revenue of RMB 1.2 billion for the fiscal year ending December 31, 2024, marking a growth of at least 25% [1] - The expected profit for 2025 is projected to be no less than RMB 50 million, a significant turnaround from a net loss of RMB 269 million in 2024 [1] Group 2: Revenue Breakdown - Content service revenue is expected to grow from RMB 577 million in 2024 to at least RMB 800 million in 2025, driven by strategic adjustments such as resource integration and new service models [1] - Information technology service revenue is projected to increase from RMB 296 million in 2024 to at least RMB 350 million in 2025, primarily due to growth in big data technology services and the launch of AI software products [1] - The company's self-developed AI software products are expected to contribute approximately RMB 30 million in revenue in their first year of launch in 2025 [1] Group 3: Operational Efficiency - The total operating expenses for 2024 are estimated to account for about 29% of revenue, with this percentage expected to decrease in 2025 as the business expands [1]

Core Viewpoint - The company, Health Road (02587.HK), anticipates significant revenue and profit growth for the fiscal year ending December 31, 2025, compared to the previous year, driven by strategic adjustments and operational efficiencies [1][2]. Group 1: Financial Projections - The company expects to achieve a revenue of no less than RMB 1.5 billion for the fiscal year 2025, representing a growth of at least 25% compared to the fiscal year 2024 [1]. - The anticipated profit for 2025 is projected to be no less than RMB 50 million, a significant turnaround from a net loss of RMB 269 million in 2024 [1]. Group 2: Revenue Growth Drivers - Content service revenue is expected to increase from RMB 577 million in 2024 to at least RMB 800 million in 2025, attributed to strategic adjustments such as resource integration and new service models [2]. - Information technology service revenue is projected to grow from RMB 296 million in 2024 to at least RMB 350 million in 2025, driven by growth in big data technology services and the launch of AI software products [2]. - The company's self-developed AI software products are expected to contribute approximately RMB 30 million in revenue in their first year of launch in 2025 [2]. Group 3: Operational Efficiency - The total operating expenses, including administrative, sales, and research expenses, accounted for about 29% of revenue in 2024, with a decrease in this percentage anticipated for 2025 as the business expands [2].

Core Viewpoint - The company expects to achieve significant revenue and profit growth in 2025, driven by strategic adjustments and new service models, following a challenging 2024 with a net loss. Group 1: Revenue Expectations - The company anticipates revenue for the fiscal year 2025 to be no less than RMB 1.5 billion, representing an increase of at least 25% compared to the fiscal year ending December 31, 2024 [1] - Content service revenue is projected to grow from RMB 577 million in 2024 to at least RMB 800 million in 2025, attributed to strategic adjustments such as resource integration and new service models [1] - Information technology service revenue is expected to rise from RMB 296 million in 2024 to at least RMB 350 million in 2025, primarily due to growth in big data technology services and the launch of AI software products [1] Group 2: Profit Expectations - The company forecasts a profit of no less than RMB 50 million for 2025, a significant turnaround from a net loss of RMB 269 million in 2024 [1] - The AI software products, developed in-house, are projected to contribute approximately RMB 30 million in revenue in their first year of launch in 2025 [1] Group 3: Operational Efficiency - The total operating expenses for 2024, including administrative, sales, and research expenses, accounted for approximately 29% of revenue [1] - The percentage of operating expenses is expected to decrease in 2025 as the business expands [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 HealthyWay Inc. 健康之路股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2587） 內幕消息 正面盈利預告 本 公 告 乃 由 健 康 之 路 股 份 有 限 公 司（「本公司」），連 同 其 附 屬 公 司 統 稱（「本 集 團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2) (a)條及香港法例第571章證券及期貨條例第XIVA部內幕消息條文而作出。 本 公 司 董 事 會（「董事會」）謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，根 據 對 本 集團截至2025年12月31日 止 年 度（「2025年 度」）的 最 新 未 經 審 核 綜 合 管 理 賬 目 及 目 前 可 得 的 其 他 資 料 ...

Group 1 - The core point of the article highlights that southbound funds increased their holdings in Health Road (02587.HK) by 306,000 shares on February 10, indicating a positive trend in investment interest [1] - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 1.9745 million shares [1] - In the last 20 trading days, southbound funds increased their holdings on 16 days, with a cumulative net increase of 10.576 million shares [1] Group 2 - As of now, southbound funds hold 191 million shares of Health Road, accounting for 21.75% of the company's total issued ordinary shares [1] - Health Road Holdings Limited primarily engages in providing enterprise services, digital marketing services, and health care services as an investment holding company [1] - The company operates its business through three segments: enterprise services and digital marketing services, health care services, and other health services and products sold through various online and offline channels [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康之路股份有限公司 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02587 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本 ...

Core Viewpoint - Health Road (02587.HK) has entered the cell therapy sector through a strategic partnership with He Yuan Bio (688238.SH), marking a significant step in building a comprehensive health service ecosystem and demonstrating its intent to rapidly position itself in the industry using a light-asset model [1][2]. Group 1: Differentiated Strategy - The industry is witnessing significant investments, such as ByteDance's 6 billion yuan commitment to a medical complex, highlighting the value of the cell therapy sector [2]. - Health Road adopts a pragmatic approach by leveraging regional agents and ecosystem collaboration, contrasting with the heavy asset investment strategies of industry giants [2]. - He Yuan Bio, a listed company on the Sci-Tech Innovation Board, has established an integrated platform for research, production, and application in cell and gene therapy, showcasing strong industrial capabilities and technical reserves [2]. Group 2: Business Model and Financial Performance - Health Road's proactive business structure optimization has led to an increase in gross margin to 31.2%, indicating improved profitability [3]. - The cell storage and preparation business typically features high gross margins and prepayment characteristics, which will further enhance the company's revenue structure and provide stable cash flow [3]. - With the cell therapy market growing at an annual rate exceeding 50%, this strategic positioning opens new growth avenues for the company [3]. Group 3: Ecosystem Synergy - The new cell therapy business can quickly integrate with Health Road's existing network of over 11,000 medical institutions, enhancing customer loyalty and service value [4]. - The company can leverage its 211.8 million registered users to introduce innovative product combinations, such as "cell storage + health assessment" and "exosome anti-aging + medical health services," maximizing user lifecycle value [4]. - By designing innovative products like "insurance + cell therapy" for partners in insurance and banking, the company can further extend its service chain [4]. Group 4: Strategic Positioning - Health Road's entry into the cell biotechnology sector represents a forward-looking strategic positioning, utilizing a light-asset and strong synergy model to tap into a high-growth market [4]. - This approach minimizes the risks associated with heavy R&D investments while maximizing the use of existing ecosystem advantages [4]. - As the business gradually takes shape and the model is validated, Health Road is expected to carve out a unique path in the cell therapy field, creating sustainable growth value for investors [4].

Core Insights - The cell therapy market is experiencing rapid growth, with an average annual growth rate exceeding 50%, and is expected to reach a market size of 58.4 billion yuan by 2030 [1] - The implementation of the new regulations for biomedical technology clinical research and application, effective from May 1, 2026, is seen as a foundational law for the industry, promoting a shift towards a comprehensive health management approach [1] Group 1: Company Strategy - Health Road has entered the cell therapy sector through a strategic partnership with He Yuan Bio, indicating its intent to build a comprehensive health service ecosystem [1][2] - The company adopts a light-asset model, focusing on regional agency as a practical approach to accelerate its growth in the cell therapy market [2] - Health Road's collaboration with He Yuan Bio, a company with a robust integrated platform in cell and gene therapy, enhances its industrial capabilities and technological reserves [2] Group 2: Market Positioning - Health Road has established a vast network with 211.8 million registered users and 905,000 registered doctors, allowing it to leverage its existing resources for rapid business expansion [2][4] - The company is focusing on three core areas: cell storage, cell preparation, and exosome preparation, aligning with its comprehensive health service system [2] - The cell storage and preparation business typically has high gross margins and prepayment characteristics, which will further optimize the company's revenue structure and provide stable cash flow [3] Group 3: Competitive Advantage - Health Road's ecosystem enables it to quickly form multi-dimensional synergies, enhancing customer loyalty and service value through its network of over 11,000 medical institutions [4] - The company can introduce innovative product combinations to its vast user base, maximizing user lifecycle value [4] - By leveraging existing resources, Health Road can achieve rapid expansion without the need to build clinical channels and user trust from scratch [4]

Group 1: 东方甄选 (Dongfang Zhenxuan) - The company reported total revenue of 2.3 billion yuan for the first half of the 2026 fiscal year, representing a year-on-year growth of 5.7%. Excluding revenue from the first half of the 2025 fiscal year prior to the split, the revenue increased by 17% year-on-year [1] - The net profit for the reporting period reached 239 million yuan [1] - The company plans to enhance its brand influence by opening its first offline experience store in Beijing and recruiting new hosts for its live streaming accounts [1] Group 2: 阿里云 (Alibaba Cloud) - Alibaba Cloud launched the full suite of cloud services for Moltbot (formerly Clawdbot), providing the necessary computing power, models, and messaging applications for users [2] - Users can quickly enable Moltbot on Alibaba Cloud's lightweight application servers or Shadow Cloud PCs and access over a hundred models from Alibaba Cloud's Qianwen series [2] - The service supports iMessage and enables interactive messaging through DingTalk, aiming to lower the technical barriers and initial costs for users deploying AI assistants [2] Group 3: 锅圈食品 (Guoquan Food) - Guoquan Food announced the establishment of an independent AI division focused on enhancing home dining experiences through smart product selection, precise recommendations, and efficient fulfillment optimization [3] - The founder emphasized a steady strategy to maintain growth while advancing structural adjustments, with a focus on digital intelligence and AI retail as core drivers [3] - The establishment of the independent AI division indicates a commitment to improving operational efficiency in the competitive food retail industry, with success dependent on effectively translating AI technology into operational benefits [3]